Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes

References

• DeFronzo RA. The triumvirate: b-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37:667–87
   Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005–12
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86
   Google Scholar
• American Diabetes Association. Clinical practice recommendations, 2002. Diabetes Care 2002;25(Suppl 1):S1–S147
   PubMedGoogle Scholar
• American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management – 2002 update. Endocr Pract 2002;8(Suppl 1):40–82
   PubMedGoogle Scholar
• Dinneen S, Gerich J, Rizza R. Carbohydrate metabolism in non–insulin-dependent diabetes mellitus. N Engl J Med 1992;327:707–13
   Google Scholar
• Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000;23:1660–5
   PubMed Web of Science ®Google Scholar
• Hu S, Wang S, Dunning BE. Glucose-dependent and glucosesensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide. Int J Exp Diabetes Res 2001;2:63–72
   Google Scholar
• Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, et al. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001;24:983–8
   PubMed Web of Science ®Google Scholar
• Fonseca VA, Kelley DE, Baron MA, Marcellari AH. Nateglinide has less potential for hypoglycemia than glyburide in subjects with type 2 diabetes and mild fasting hyperglycemia [abstract]. Diabetes 2002;51(Suppl 2):A470
   Google Scholar
• Merz M, Walter YH, Brookman L, Ma P, Gerich JE, McLeod JF. Risk of delayed hypoglycemia is reduced with nateglinide compared to repaglinide [abstract]. Diabetologia 2000;43(Suppl 1):A186
   Google Scholar
• Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787–94
   PubMed Web of Science ®Google Scholar
• Båvenholm PN, Pigon J, Östenson C-G, Efendic S. Insulin sensitivity of suppression of endogenous glucose production is the single most important determinant of glucose tolerance. Diabetes 2001;50:1449–54
   Google Scholar
• Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs 1999;58(Suppl 1):31–9
   PubMedGoogle Scholar
• Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001;286:1195–200
   PubMed Web of Science ®Google Scholar
• Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995;18:258–68
   PubMed Web of Science ®Google Scholar
• Boden G, Ruiz J, Kim CJ, Chen X. Effects of prolonged glucose infusion on insulin secretion, clearance, and action in normal subjects. Am J Physiol 1996;270:E251–E258
   PubMed Web of Science ®Google Scholar
• Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 2002;4: 201–8
   Google Scholar
• Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156–63
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–12
   PubMed Web of Science ®Google Scholar
• Raskin P, Gerich J, Jean-Louis L, Purkayastha D, Baron M. The PRESERVE-b trial: rationale, design and early data [abstract]. Diabetes 2003;52(Suppl 1):A130
   Google Scholar